Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Unanswered questions in early breast cancer care at St Gallen 2025

Orit Kaidar-Person • 13 Mar 2025
BCC 2025
Breast Cancer

Orit Kaidar-Person, MD, Sheba Medical Center, Ramat Gan, Israel, comments on the importance of considering risk factors and population-specific approaches in early breast cancer, highlighting the need for personalized therapy optimization. Prof. Kaidar-Person also notes the potential for proton therapy to be explored as a treatment option for patients with breast cancer, although the current evidence is limited. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Orit Kaidar-Person

The role of regional node irradiation for low-burden breast cancer
0:53
The role of regional node irradiation for low-burden breast cancer
Orit Kaidar-Person • 13 Mar 2025
Do all low-burden breast cancer cases need regional node irradiation?
0:50
Do all low-burden breast cancer cases need regional node irradiation?
Orit Kaidar-Person • 13 Mar 2025
Indicating radiotherapy after breast-conserving therapy & mastectomy
1:28
Indicating radiotherapy after breast-conserving therapy & mastectomy
Orit Kaidar-Person • 13 Mar 2025
Tailoring radiation therapy for breast cancer based on recurrence risk
1:05
Tailoring radiation therapy for breast cancer based on recurrence risk
Orit Kaidar-Person • 16 May 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals